Virginia Enfamil Necrotizing Enterocolitis injury lawyer
For years, Elmiron (pentosan polysulfate sodium) was the only FDA-approved oral medication for interstitial cystitis, a chronic bladder condition. But by the mid-2020s, the medical and legal communities had confirmed what many North Carolina patients feared: long-term Elmiron use can cause irreversible pigmentary maculopathy, a degenerative eye disease that leads to vision loss. As of 2026, the litigation landscape has shifted significantly, but thousands of North Carolinians who took this drug still haven't received compensation. Our team continues to represent clients across the state, from Charlotte to Raleigh to Asheville, who are fighting for accountability after their vision was stolen by a drug that was supposed to help them.
The Elmiron MDL and the 2024 Settlement: What Changed and What Didn't
The multidistrict litigation (MDL) against Janssen Pharmaceuticals, the maker of Elmiron, was consolidated in the District of New Jersey. By late 2024, a global settlement framework was announced for many of the approximately 2,000 pending cases. Under the terms, qualifying plaintiffs could receive compensation based on the severity of their maculopathy, duration of Elmiron use, and age at diagnosis. However, the settlement was not a blanket admission of liability, and it left critical gaps. Many North Carolina patients who used Elmiron for fewer than five years or who have early-stage disease without significant vision loss were excluded or offered minimal payouts. Furthermore, the settlement did not cover future claims from patients who have not yet been diagnosed. This means that for anyone in North Carolina who took Elmiron and is now experiencing symptoms like blurred vision, difficulty reading, or trouble adjusting to dim light, the window to file a claim is still open—but it won't stay open forever.
"The Elmiron settlement was a step forward, but it was never a finish line. In North Carolina, we are still seeing new cases of pigmentary maculopathy diagnosed in patients who took the drug a decade ago. The statute of limitations in this state is complex, and every day that passes without legal action is a day a victim might lose their right to recover."
— Source: respondingtoaidsexhibit.org | Archive reference
Why North Carolina's Statute of Limitations Demands Immediate Action in 2026
North Carolina law generally allows three years from the date of injury to file a product liability lawsuit. But for Elmiron maculopathy, the "date of injury" is a moving target. Many patients were diagnosed years after they stopped taking the drug, and the progressive nature of the disease means that vision loss can worsen long after initial diagnosis. Our firm has successfully argued that the clock should start from the date a patient reasonably connected their vision problems to Elmiron use—often after reading news reports or seeing a specialist. In 2026, however, courts are becoming less lenient. Several North Carolina judges have begun dismissing cases where plaintiffs waited more than five years after their diagnosis to file, even if they didn't know the cause. If you or a loved one took Elmiron and have any vision changes, you need to speak with an attorney immediately. The legal window is narrowing.
How We Build Your Elmiron Case: From Medical Records to Expert Testimony
Winning an Elmiron injury claim in North Carolina requires more than just a prescription history. We follow a rigorous process to prove causation and damages. Here is our standard approach:
- Comprehensive medical record review: We obtain all records from your urologist (confirming Elmiron prescription and duration) and your ophthalmologist (documenting macular changes via OCT, fundus autofluorescence, and visual field tests).
- Retinal imaging analysis: We work with board-certified retinal specialists who can identify the characteristic pattern of Elmiron toxicity—often a bilateral, symmetric maculopathy with pigmentary changes in the parafoveal region.
- Exclusion of other causes: We ensure that age-related macular degeneration, pattern dystrophy, and other hereditary conditions are ruled out, strengthening the causal link to Elmiron.
- Expert witness coordination: We retain leading ophthalmologists and pharmacologists who have published on Elmiron toxicity to provide testimony on the drug's known risks and the manufacturer's failure to warn.
Below is a summary of how different stages of maculopathy typically correlate with settlement values in North Carolina cases as of 2026:
| Maculopathy Stage | Typical Symptoms | Estimated Settlement Range (2026) |
|---|---|---|
| Stage 1 (Early) | Mild pigmentary changes; no significant vision loss | $25,000 – $75,000 |
| Stage 2 (Moderate) | Blurred vision, difficulty reading, paracentral scotomas | $100,000 – $250,000 |
| Stage 3 (Advanced) | Legal blindness, significant central vision loss | $300,000 – $600,000+ |
Note: These ranges are estimates based on recent North Carolina settlements and verdicts. Actual compensation depends on individual factors including lost wages, medical expenses, and pain and suffering.
If you live in North Carolina and took Elmiron, don't assume it's too late. The drug's manufacturer knew about the risk of pigmentary maculopathy years before they updated the label, and they failed to warn patients and doctors. We are still accepting new cases in 2026, and we are ready to fight for your vision—and your future.